These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

298 related items for PubMed ID: 16876363

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. The efficacy of cefditoren pivoxil in the treatment of lower respiratory tract infections, with a focus on the per-pathogen bacteriologic response in infections caused by Streptococcus pneumoniae and Haemophilus influenzae: a pooled analysis of seven clinical trials.
    Granizo JJ, Giménez MJ, Barberán J, Coronel P, Gimeno M, Aguilar L.
    Clin Ther; 2006 Dec; 28(12):2061-9. PubMed ID: 17296462
    [Abstract] [Full Text] [Related]

  • 3. [Antibiotherapy for acute CAP in adults].
    Denes E.
    Med Mal Infect; 2006 Dec; 36(11-12):718-33. PubMed ID: 17092678
    [Abstract] [Full Text] [Related]

  • 4. Therapeutic options for pneumococcal pneumonia in Turkey.
    Oncu S, Erdem H, Pahsa A.
    Clin Ther; 2005 Jun; 27(6):674-83. PubMed ID: 16117975
    [Abstract] [Full Text] [Related]

  • 5. Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia.
    Feldman C.
    J Lab Clin Med; 2004 May; 143(5):269-83. PubMed ID: 15122171
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Garenoxacin activity against isolates form patients hospitalized with community-acquired pneumonia and multidrug-resistant Streptococcus pneumoniae.
    Jones RN, Sader HS, Stilwell MG, Fritsche TR.
    Diagn Microbiol Infect Dis; 2007 May; 58(1):1-7. PubMed ID: 17408904
    [Abstract] [Full Text] [Related]

  • 10. Antimicrobial selection for community-acquired lower respiratory tract infections in the 21st century: a review of gemifloxacin.
    Appelbaum PC, Gillespie SH, Burley CJ, Tillotson GS.
    Int J Antimicrob Agents; 2004 Jun; 23(6):533-46. PubMed ID: 15194123
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Efficacy of moxifloxacin for treatment of penicillin-, macrolide- and multidrug-resistant Streptococcus pneumoniae in community-acquired pneumonia.
    Fogarty C, Torres A, Choudhri S, Haverstock D, Herrington J, Ambler J.
    Int J Clin Pract; 2005 Nov; 59(11):1253-9. PubMed ID: 16236076
    [Abstract] [Full Text] [Related]

  • 13. Risk factors and clinical outcomes of penicillin resistant S. pneumoniae community-acquired pneumonia in Khon Kaen, Thailand.
    Reechaipichitkul W, Assawasanti K, Chaimanee P.
    Southeast Asian J Trop Med Public Health; 2006 Mar; 37(2):320-6. PubMed ID: 17124993
    [Abstract] [Full Text] [Related]

  • 14. Principles of antibiotic treatment of community-acquired pneumonia in the outpatient setting.
    Segreti J, House HR, Siegel RE.
    Am J Med; 2005 Jul; 118 Suppl 7A():21S-28S. PubMed ID: 15993674
    [Abstract] [Full Text] [Related]

  • 15. Antimicrobial susceptibilities of Streptococcus pneumoniae isolated from adult patients with community-acquired pneumonia in Japan.
    Ishida T, Maniwa K, Kagioka H, Hirabayashi M, Onaru K, Tomioka H, Hayashi M, Tomii K, Gohma I, Ito Y, Hirai T, Ito I, Mishima M.
    Respirology; 2008 Mar; 13(2):240-6. PubMed ID: 18339022
    [Abstract] [Full Text] [Related]

  • 16. Streptococcus pneumoniae: does antimicrobial resistance matter?
    Lynch JP, Zhanel GG.
    Semin Respir Crit Care Med; 2009 Apr; 30(2):210-38. PubMed ID: 19296420
    [Abstract] [Full Text] [Related]

  • 17. Placebo-controlled trials of treatments for community-acquired pneumonia: review of the literature and discussion of feasibility and potential value.
    Murphy TF.
    Clin Infect Dis; 2008 Dec 01; 47 Suppl 3():S145-9. PubMed ID: 18986281
    [Abstract] [Full Text] [Related]

  • 18. Doxycycline use for community-acquired pneumonia: contemporary in vitro spectrum of activity against Streptococcus pneumoniae (1999-2002).
    Jones RN, Sader HS, Fritsche TR.
    Diagn Microbiol Infect Dis; 2004 Jun 01; 49(2):147-9. PubMed ID: 15183865
    [Abstract] [Full Text] [Related]

  • 19. Clarithromycin in the management of community-acquired pneumonia.
    McCarty JM.
    Clin Ther; 2000 Mar 01; 22(3):281-94; discussion 265. PubMed ID: 10963284
    [Abstract] [Full Text] [Related]

  • 20. Scenario 1: a patient with mild community-acquired pneumonia--introduction to clinical trial design issues.
    Gilbert DN.
    Clin Infect Dis; 2008 Dec 01; 47 Suppl 3():S121-2. PubMed ID: 18986276
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.